TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

By Dr. Matthew Watson

UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen

The rest is here:
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference - February 20th, 2025
NAYA Biosciences Announces Nomination of New Board Members - February 20th, 2025
Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology - February 20th, 2025
OrphAI Therapeutics Announces Appointment of Dr. Aaron Waxman to Board of Directors - February 20th, 2025
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate - February 20th, 2025
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers - February 20th, 2025
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock - February 20th, 2025
Better Choice Company Adjourns Special Meeting of Stockholders to March 21, 2025 - February 20th, 2025
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing - February 20th, 2025
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - February 20th, 2025
GRI Bio Announces Reverse Stock Split - February 20th, 2025
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference - February 20th, 2025
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March - February 20th, 2025
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock - February 20th, 2025
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - February 20th, 2025
Zealand Pharma Announces Financial Results for the Full Year 2024 - February 20th, 2025
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 - February 20th, 2025
EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform... - February 20th, 2025
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - February 20th, 2025
Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders - February 20th, 2025
Grace Therapeutics Announces Private Placement Financing of up to $30 Million - February 11th, 2025
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - February 11th, 2025
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience - February 11th, 2025
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - February 11th, 2025
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy - February 11th, 2025
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial - February 11th, 2025
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology /... - February 11th, 2025
Capricor Therapeutics to Participate in Upcoming Investor Conferences - February 11th, 2025
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - February 11th, 2025
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - February 11th, 2025
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory... - February 11th, 2025
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol - February 11th, 2025
Revolo to Present at the 2025 AAAAI / WAO Joint Congress - February 11th, 2025
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - February 11th, 2025
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - February 11th, 2025
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 11th, 2025
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - February 11th, 2025
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - February 11th, 2025
Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance - February 11th, 2025
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront - February 11th, 2025
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange - January 31st, 2025
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - January 31st, 2025
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - January 31st, 2025
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - January 31st, 2025
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - January 31st, 2025
Avid Stockholders Approve Transaction with GHO and Ampersand - January 31st, 2025
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - January 31st, 2025
Portage Biotech Announces Completion of $2.15 Million Private Financing - January 31st, 2025
Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision... - January 31st, 2025
Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - January 31st, 2025
Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - January 31st, 2025
Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - January 31st, 2025
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - January 31st, 2025
BioSyent Declares First Quarter 2025 Dividend - January 31st, 2025
Tarsus to Participate in Upcoming Investor Conferences - January 31st, 2025
Ryoncil® Commercial Launch Update and Product Pipeline - January 31st, 2025
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - January 31st, 2025
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - January 31st, 2025
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for... - January 31st, 2025
Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update - January 31st, 2025
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 22nd, 2025
Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 22nd, 2025
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 22nd, 2025
Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 22nd, 2025
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 22nd, 2025
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 22nd, 2025
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31,... - January 22nd, 2025
RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue - January 22nd, 2025
Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - January 22nd, 2025
Pharming Group to convene Extraordinary General Meeting of Shareholders - January 22nd, 2025
BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders - January 22nd, 2025
Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments - January 22nd, 2025
Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd - January 22nd, 2025
Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 - January 22nd, 2025
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director - January 22nd, 2025
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO... - January 22nd, 2025
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in... - January 22nd, 2025
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible... - January 22nd, 2025
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - January 22nd, 2025
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care - January 22nd, 2025

Global News Feed commento

Comments Off | data

February 6th, 2021

About... Dr. Matthew Watson

This author published 6052 posts in this site.

Comments are closed.

Previous post - Next post

TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites